Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Assembly Biosciences (ASMB) over the last 16 years, with Dec 2024 value amounting to $6.4 million.

  • Assembly Biosciences' Shares Outstanding (Weighted Average) rose 20.91% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 20.91%. This contributed to the annual value of $6.4 million for FY2024, which is 16.08% up from last year.
  • As of FY2024, Assembly Biosciences' Shares Outstanding (Weighted Average) stood at $6.4 million, which was up 16.08% from $5.5 million recorded in FY2023.
  • In the past 5 years, Assembly Biosciences' Shares Outstanding (Weighted Average) registered a high of $6.4 million during FY2024, and its lowest value of $2.8 million during FY2020.
  • In the last 3 years, Assembly Biosciences' Shares Outstanding (Weighted Average) had a median value of $5.5 million in 2023 and averaged $5.3 million.
  • Data for Assembly Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 44.94% (in 2021) over the last 5 years.
  • Over the past 5 years, Assembly Biosciences' Shares Outstanding (Weighted Average) (Yearly) stood at $2.8 million in 2020, then soared by 44.94% to $4.0 million in 2021, then increased by 1.92% to $4.1 million in 2022, then surged by 34.71% to $5.5 million in 2023, then increased by 16.08% to $6.4 million in 2024.